S-1: Cingulate Secures $25 Million Equity Line, Advances ADHD Drug Towards NDA

Cingulate Inc. has entered into a new $25 million committed equity financing agreement with Lincoln Park Capital Fund, LLC, while progressing its lead ADHD drug candidate, CTx-1301, towards an anticipated NDA submission by early August 2025.

Summary

• A registration statement on Form S-1 has been filed for the resale of up to 2,500,000 shares of common stock by Lincoln Park Capital Fund, LLC.
• The shares include 120,424 Commitment Shares already issued as a fee and up to 2,379,576 Purchase Shares that Cingulate Inc. may sell to Lincoln Park at its discretion.
• A new Purchase Agreement, dated July 21, 2025, provides up to $25.0 million in committed equity financing over a 36-month period.
• Cingulate Inc. will not receive proceeds from Lincoln Park's resale of shares, but may receive up to $25.0 million from its direct sales of Purchase Shares to Lincoln Park.
• Proceeds from sales to Lincoln Park are earmarked for regulatory approval, development, manufacturing, and commercialization activities for CTx-1301, as well as for working capital and general corporate purposes.
• Cingulate Inc. is a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTRTM) drug delivery platform, initially focusing on Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety.
• The company is developing CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for ADHD, targeting a U.S. market estimated at over $23 billion as of November 2023, with stimulants accounting for $18.6 billion.
• Enrollment for two CTx-1301 Phase 3 pediatric and adolescent clinical studies has been closed, following communication from the FDA that further conduct of these studies is not required for NDA submission.
• Safety data from the closed CTx-1301 Phase 3 trials and a food effect study indicated no serious treatment emergent adverse events (TEAEs) or clinically relevant trends.
• The New Drug Application (NDA) for CTx-1301 is anticipated to be submitted by the end of July or early August 2025.
• Cingulate Inc.'s common stock and warrants are listed on the Nasdaq Capital Market LLC under the symbols CING and CINGW, respectively.
• The last reported sale price of common stock on Nasdaq on July 18, 2025, was $5.17 per share.
• The company qualifies as an emerging growth company, benefiting from reduced public company reporting requirements.

Sentiment

Score: 6

Explanation: The filing indicates a significant positive step in securing committed equity financing, which is crucial for the company's liquidity and continued drug development, especially given the prior 'going concern' warning. The progress towards CTx-1301 NDA submission is also a strong positive. However, the inherent dilution from the equity line and the ongoing financial challenges temper the overall sentiment, suggesting a cautiously optimistic outlook.

Positives

• Secured up to $25.0 million in committed equity financing from Lincoln Park Capital, providing a flexible funding source for operations and drug development.
• FDA communication indicates that further pediatric and adolescent studies for CTx-1301 are not required for NDA submission, potentially accelerating the regulatory pathway.
• Safety data from CTx-1301 Phase 3 trials showed no serious treatment emergent adverse events (TEAEs) or clinically relevant trends, supporting a favorable safety profile.
• Anticipated NDA submission for CTx-1301 by the end of July or early August 2025 marks a significant milestone towards potential commercialization.
• Proprietary Precision Timed Release (PTRTM) drug delivery platform offers the potential for once-daily, multi-dose tablets, addressing a significant unmet need in ADHD treatment.
• Product candidates CTx-1301 and CTx-1302 are designed to provide entire active-day coverage and improved side effect profiles, aiming to reduce the need for booster doses and associated issues.

Negatives

• The sale of common stock to Lincoln Park will result in substantial dilution to existing stockholders' economic and voting interests.
• The purchase price for shares sold to Lincoln Park fluctuates based on market prices, which could lead to sales at lower prices and increased dilution.
• Limitations on share issuance to Lincoln Park, such as the Nasdaq Exchange Cap (1,004,660 shares or 19.99% without stockholder approval, unless average price exceeds $5.6537) and the Beneficial Ownership Cap (4.99%, or 9.99% with notice), may restrict the company's ability to fully utilize the $25.0 million commitment without further actions.
• The audit report for the fiscal year ended December 31, 2024, includes an explanatory paragraph indicating that losses and negative cash flows from operations raise substantial doubt about the entity's ability to continue as a going concern.
• The company has a 'lack of operating history and need for additional capital' as a stated risk factor.

Risks

• Inability to predict the actual number of shares sold to Lincoln Park or the aggregate gross proceeds due to fluctuating market prices of common stock.
• Lincoln Park may sell acquired shares at varying prices, and such sales, or the anticipation of them, could cause the price of common stock to decrease.
• Limitations on share issuance to Lincoln Park (Exchange Cap, Beneficial Ownership Cap) may hinder the company's ability to fully access the committed capital, potentially necessitating more costly and time-consuming alternative financing.
• Future sales of common stock to Lincoln Park, or the expectation of such sales, could make it more difficult for the company to raise equity capital in the future at favorable terms.
• Management has broad discretion over the use of net proceeds from sales to Lincoln Park, and these proceeds may not be invested successfully.
• Investment in the company's securities is highly speculative and involves a high degree of risk, potentially leading to a loss of the entire investment.
• Risks related to maintaining compliance with Nasdaq's continued listing requirements.
• Uncertainties regarding the timing of planned clinical trials and the ability to obtain and maintain regulatory approvals for product candidates (CTx-1301, CTx-1302, CTx-2103).
• Risks associated with the clinical utility of product candidates and the ability to successfully commercialize, market, and manufacture them.
• Challenges in identifying strategic partnerships and recruiting and retaining key personnel.
• The impact of laws and regulations on business operations.
• Uncertainty regarding whether a court would enforce the exclusive forum provision for claims under the Securities Act.

Future Outlook

The company anticipates submitting the New Drug Application (NDA) for CTx-1301 by the end of July or early August 2025. Proceeds from the new $25.0 million committed equity financing are expected to be used to obtain regulatory approval and for development, manufacturing, and commercialization activities of CTx-1301, as well as for working capital, capital expenditures, and general corporate purposes, including investing further in research and development efforts. The company also plans to identify additional product candidates with significant commercial potential.

Industry Context

Cingulate operates within the biopharmaceutical industry, specifically targeting the large and growing ADHD and anxiety treatment markets. Its proprietary Precision Timed Release (PTRTM) drug delivery platform aims to differentiate its product candidates, CTx-1301 and CTx-1302, by addressing key shortcomings of existing stimulant therapies, such as the need for multiple daily doses and suboptimal side effect profiles. The U.S. ADHD market, particularly the stimulant segment, represents a substantial commercial opportunity, with an estimated size of over $23 billion. By offering a true once-daily medication with extended coverage and improved tolerability, Cingulate seeks to capture market share from current extended-release stimulant medications that often require booster doses, potentially offering significant societal and economic benefits.

Comparison to Industry Standards

• CTx-1301 and CTx-1302 are designed to provide a near immediate onset of action (within 30 minutes) and entire active-day duration, aiming to surpass the performance of many current once-daily extended-release ADHD stimulant medications that often necessitate a second or booster dose later in the day.
• The company's product candidates seek to eliminate the need for booster/recovery doses of additional stimulant medications, directly addressing a common patient and physician challenge with existing therapies.
• CTx-1301 and CTx-1302 are designed to minimize or eliminate the rebound/crash symptoms associated with early medication wear-off and provide favorable tolerability with a controlled descent of drug blood levels, aiming for a superior side effect profile compared to current market offerings.
• By potentially eliminating the booster dose, the company believes its product candidates will offer important societal and economic benefits, including reducing abuse and diversion associated with short-acting stimulant medications, allowing physicians to prescribe one medication versus two, and enabling patients and payers to pay for one medication versus two, contrasting with the current multi-medication treatment paradigm.

Management Changes

Corporate Governance

Related Party Transactions

• Promissory note issued to Werth Family Investment Associates LLC (WFIA) on August 9, 2022, and subsequently amended on May 9, 2023, to increase the principal amount to $8.0 million. Peter J. Werth, a member of the Board of Directors, is the manager of WFIA.
• Private placement of 7,597 shares of common stock to WFIA on August 11, 2023, for approximately $1.0 million.
• Note conversion agreement with WFIA on September 8, 2023, converting $5,812,500 of debt and accrued interest into pre-funded warrants.
• Note conversion agreement with WFIA on January 25, 2024, converting the remaining $3.0 million of principal and accrued interest into pre-funded warrants.
• Issuance of an additional pre-funded warrant to WFIA on March 25, 2024, due to an error in interest calculation.

Stakeholder Impact

• Shareholders face potential significant dilution of their economic and voting interests due to the issuance of new common stock under the Purchase Agreement, especially if shares are sold at lower market prices.
• The company gains crucial liquidity and access to up to $25.0 million in capital, which is vital for funding ongoing drug development, regulatory processes, manufacturing, and commercialization activities, addressing the 'going concern' issue.
• Lincoln Park Capital Fund, LLC benefits from the ability to purchase shares at a discount to market prices and resell them, acting as a committed financing partner.
• Patients suffering from ADHD and anxiety could potentially benefit from new, improved treatment options if CTx-1301 and CTx-1302 successfully achieve regulatory approval and commercialization, offering once-daily dosing and better side effect profiles.
• Physicians and payers may experience benefits from simplified prescribing and potentially reduced costs if the company's products eliminate the need for multiple daily doses and associated medications.

Next Steps

• The SEC must declare the registration statement effective for the company to commence sales of common stock to Lincoln Park.
• The company will perform data consolidation and analytical activities for the closed CTx-1301 Phase 3 trials.
• The company anticipates submitting the New Drug Application (NDA) for CTx-1301 by the end of July or early August 2025.
• The company may elect to issue and sell Purchase Shares to Lincoln Park from time to time over a 36-month period after the Commencement Date.
• The company plans to identify and evaluate additional therapeutic areas where its PTR technology may be employed to develop future product candidates.
• The company may need to register additional shares for resale under the Securities Act to receive aggregate gross proceeds equal to the full $25.0 million commitment available under the Purchase Agreement.
• Management may use a portion of the net proceeds to acquire or invest in complementary businesses, technologies, product candidates, or other intellectual property.

Key Dates

Recommendation

The committed equity financing provides a critical lifeline for Cingulate, addressing immediate liquidity concerns and enabling continued progress on its drug pipeline, particularly the anticipated NDA submission for CTx-1301. This is a significant positive development for a company with a 'going concern' warning. However, the substantial potential for dilution from the equity line, coupled with the inherent high risks of a clinical-stage biopharmaceutical company with no approved products, warrants a 'Hold' recommendation. Investors should closely monitor the outcome of the NDA submission, the terms and pace of share issuances under the Lincoln Park agreement, and the company's ability to manage dilution while advancing its pipeline towards commercialization.

Keywords

Biopharmaceutical, ADHD, Attention Deficit/Hyperactivity Disorder, Drug Delivery, Precision Timed Release, PTRTM, CTx-1301, CTx-1302, Dexmethylphenidate, Dextroamphetamine, Anxiety, Equity Financing, Lincoln Park Capital, Committed Equity Facility, Dilution, Clinical Trials, NDA Submission, Nasdaq, Emerging Growth Company, Pharmaceutical Development, Capital Raise